Results 251 to 260 of about 87,574 (284)

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

The Journal of Dermatology, EarlyView.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki, Ryo Saito, Kenta Suzuki, Daisuke Watanabe, Masako Minami‐Hori, Hirofumi Kamada, Hiroo Amano, Akihiko Uchiyama, Sei‐ichiro Motegi, Machiko Kamura, Kazunari Sugita, Noriko Kubota, Toshifumi Nomura, Maki Ozawa, Toshiya Takahashi, Takashi Yamakita, Kazumitsu Sugiura, Tetsuharu Ikegami, Ken Igawa, Yuka Kimura, Yoko Kataoka, Ryoichi Kamide, Masakazu Takahashi, Akio Tanaka, Mariko Sugawara‐Mikami   +24 more
wiley   +1 more source

Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study

The Journal of Dermatology, EarlyView.
ABSTRACT Tralokinumab, an anti‐IL‐13 antibody, is effective for atopic dermatitis (AD); however, its long‐term (> 1 year) effectiveness specific to each anatomical site is unknown in real‐world settings. To evaluate 72‐week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate‐to‐severe AD treated with
Mizuki Shiba, Teppei Hagino, Akihiko Uchiyama, Hidehisa Saeki, Eita Fujimoto, Sei‐ichiro Motegi, Naoko Kanda   +6 more
wiley   +1 more source

International Evidence‐Based Guidelines for Traditional Chinese Medicine Management of Allergic Rhinitis

Allergy, EarlyView.
ABSTRACT Allergic rhinitis (AR) is a prevalent chronic condition that significantly impacts patients' quality of life and poses challenges to effective management. Traditional Chinese medicine (TCM) offers a holistic approach, emphasizing syndrome differentiation, individualized care, and natural treatment strategies.
Qin‐Wei Fu, Peng Liu, Yan Ruan, Xin‐Rong Li, Lan‐Zhi Zhang, Sha‐Sha Yang, Feng Chai, Ji Chen, Qiao‐Yan Chen, Shu‐Cheng Chen, Wen‐Yong Chen, Yong‐Na Chen, Hong‐Bin Cheng, Lei Cheng, Lu‐Jia Cui, Ke‐Bin Deng, Cai‐Shan Fang, Rong‐Chang Feng, Li Fu, Wen‐Yang Fu, Jian‐Ying Gao, Hong Guo, Miao He, Ko‐Hsin Hu, Chun‐Jiang Huang, He‐Yin Huang, Lu‐Yun Jiang, Feng‐Ying Qiao, Hui Leng, Yun‐Ying Li, Chun‐Song Liu, Da‐Xin Liu, Jian‐Hua Liu, Jin‐Hui Liu, Jing Liu, Min Liu, Wei‐Ting Liu, Yuan‐Xian Liu, Yang Liu, Ying Liu, Zhi‐Qing Liu, Qiu‐Lan Luo, Yu Ma, De‐Hong Mao, Juan Meng, Kai‐Yun Pang, Shun‐Lin Peng, Xuan‐Fu Tong, Ji Wang, Jia‐Xi Wang, Jun‐Ge Wang, Ren‐Zhong Wang, Shi‐Zhen Wang, Ji‐Yan Xia, Hui Xie, Qiang Xie, Yan Xie, Da‐Jing Xiong, Zhan‐Feng Yan, Hui Yang, Da‐Zheng Zhang, Fu‐Bing Zhang, Shi‐Peng Zhang, Zhi‐Cheng Zhang, Ji‐Ping Zhao, Yu Zhao, Yun Zheng, Dan‐Zhu Zhong, Li Zhou, Valentin Mikhailovich Knyazev, Irina Viktorovna Kostrova, Wing‐Fai Yeung, Qi Wang, De‐Yun Wang, Qin‐Xiu Zhang   +74 more
wiley   +1 more source

Effect of the Arg16Gly β2‐Adrenergic Receptor Polymorphism on Long‐Term Mepolizumab Response and Clinical Remission in Severe Eosinophilic Asthma: A Genotype‐Stratified, Multicenter Study

Allergy, EarlyView.
This study examines the association between the rs1042713 (Arg16Gly) polymorphism of the β2‐adrenergic receptor and the risk of severe eosinophilic asthma, as well as its influence on mepolizumab long‐term effectiveness and clinical remission. The Arg16 allele is associated with increased risk of severe disease and potentially diminished long‐term ...
Santi Nolasco, Evelina Fagone, Raffaele Campisi, Andrea Portacci, Giulia Scioscia, Corrado Pelaia, Angelantonio Maglio, Claudio Candia, Vitaliano Nicola Quaranta, Isabella Carrieri, Alessandro Saglia, Alessandro Vatrella, Girolamo Pelaia, Carlo Vancheri, Maria Pia Foschino Barbaro, Maria D'Amato, Giovanna Elisiana Carpagnano, Nunzio Crimi, Claudia Crimi, on behalf of the Southern Italy Network on Severe Asthma Therapy, Rossella Intravaia, Morena Porto, Pietro Impellizzeri, Maria Provvidenza Pistorio, Fabio Vignera, Andrea Alessia Nardo, Concetta Giannì, Silvano Dragonieri, Flogerta Sana, Valeria Pezzuto, Santina Ferulli, Massimo Triggiani, Roberta Parente, Pasquale Tondo, Piera Soccio, Donato Lacedonia, Luigi Ciampo, Antonio Franzese, Valeria Longobardi   +38 more
wiley   +1 more source

Prolonged IL‐33 Exposure Switches the Secreted Mast Cell Cytokine Profile From Pro‐Inflammatory to Pro‐Tolerant

Allergy, EarlyView.
This study investigates the effect of IL‐33 and Hymenoptera venom on mast cell cytokine profiles under venom immunotherapy (VIT)‐like conditions. Our in vitro model of VIT‐like mast cell stimulation demonstrates a modulatory effect of IL‐33 on the secreted mast cell cytokine profile.
Andrea R. Teufelberger, Carolin Költgen, Magda Babina, Peter Wolf   +3 more
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Subcutaneous immunoglobulin substitution and therapy

Orvosi Hetilap, 2011
Patients with combined primary immunodeficiency or B-cell deficiency with low serum concentration of immunoglobulin G can be efficiently treated with immunoglobulin G concentrates. From the 1950s IgG was used intramuscularly, and from the 1980s intravenous immunoglobulin (IVIG) replacement has become widely available for replacement therapy.
Vera, Gulácsy, László, Maródi
openaire   +2 more sources

Subcutaneous Immunoglobulin Replacement Therapy

Journal of Infusion Nursing, 2015
Subcutaneous immunoglobulin (SCIg) infusions are an option for patients requiring immunoglobulin therapy. Nurses are uniquely positioned to advocate for patients and to teach them how to successfully manage their infusions. The purpose of this review is to describe SCIg therapy and to provide teaching instructions as well as creative tips to ensure ...
M Elizabeth M, Younger, William, Blouin, Carla, Duff, Kristin Buehler, Epland, Elyse, Murphy, Debra, Sedlak   +5 more
openaire   +2 more sources

Susac Syndrome Treated with Subcutaneous Immunoglobulin

European Neurology, 2013
<b><i>Background:</i></b> Susac syndrome is a rare disease characterized by the triad of encephalopathy, branch retinal artery occlusion, and sensorineural hearing loss mainly affecting young women. The finding of antibodies against the endothelium in the sera of these patients has supported the hypothesis of an autoimmune ...
Ilka, Kleffner, Jan, Dörr, Thomas, Duning, Peter, Young, E Bernd, Ringelstein, Matthias, Schilling   +5 more
openaire   +2 more sources

Subcutaneous Immunoglobulin in Refractory Juvenile Dermatomyositis

Pediatrics, 2016
Juvenile dermatomyositis (JDM) is the most common form of juvenile idiopathic inflammatory myopathy. We report a child with steroid-dependent JDM refractory to hydroxychloroquine and subcutaneous methotrexate who experienced systemic reactions to intravenous immunoglobulin and was successfully treated with subcutaneous immunoglobulin.
Jaime, de Inocencio, Eugenia, Enríquez-Merayo, Rocío, Casado, Luis Ignacio, González-Granado   +3 more
openaire   +2 more sources

Subcutaneous Administrationof Immunoglobulin

Journal of Infusion Nursing, 2006
Subcutaneous infusion of immunoglobulin has emerged as an alternative administration method for both children and adults. It is well tolerated, safe, clinically efficacious, and appreciated by patients. This article provides an overview of subcutaneous immunoglobulin administration advantages and disadvantages, the administration procedure, the ...
openaire   +2 more sources